Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model

References

• Alonso MJ, Sanchez A, Torres D, Seijo B, Vila-Jato JL. Joint effects of monomer and stabilizer concentrations on physico-chemical characteristics of poly(butyl 2-cyanoacrylate) nanoparticles. Journal of Microencapsulation 1990; 7: 517–526
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro. Journal of Drug Targeting 2001; 9: 209–221
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Kholonsky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [19C]-poly(butylcyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of Drug Targeting 2006; 14: 103–111
   Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacology and Therapeutics 2004; 104: 29–45
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Wiese G, Underberg WJ. Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution. Pharmaceutical Weekblaat Science 1985; 7: 109–116
   PubMedGoogle Scholar
• Calvo P, Gouritin B, Chacun H, Desmaele D, D’Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research 2001; 18: 1157–1166
   PubMed Web of Science ®Google Scholar
• Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chemical and Pharmaceutical Bulletin, Tokyo 2001; 49: 1444–1447
   PubMed Web of Science ®Google Scholar
• Douglas S, Illum L, Davis SS. Particle size and size distribution of poly(butyl 2-cyano acrylate) nanoparticles. II: Influence of the stabilizer. Journal of Colloid and Interface Science 1985; 103: 154–163
   Web of Science ®Google Scholar
• Douglas S, Illum L, Davis SS, Kreuter J. Particle size and size distribution of poly(butyl 2-cyano acrylate) nanoparticles. I: Influence of physicochemical factors. Journal of Colloid and Interface Science 1984; 101: 149–158
   Web of Science ®Google Scholar
• Fang J, Sawa T, Maeda H. Factors and mechanism of ‘EPR’ effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Advances in Experimental Medical Biology 2003; 519: 29–49
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research 1999; 16: 1564–1569
   PubMed Web of Science ®Google Scholar
• Kante B, Couvreur P, Dubois-Krack G, De Meester C, Guiot P, Roland M, Mercier M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. Journal of Pharmaceutical Sciences 1982; 71: 786–790
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Advances in Drug Delivery Reviews 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. Current Medical Chemistry—Central Nervous System Agents 2002; 2: 241–249
   Google Scholar
• Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles. Journal of Controlled Release 1997; 49: 81–87
   Web of Science ®Google Scholar
• Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research 2003; 20: 409–16
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin RN. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of Drug Targeting 2002; 10: 317–325
   PubMed Web of Science ®Google Scholar
• Langer K, Seegmüller E, Zimmer A, Kreuter J. Characterization of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans. International Journal of Pharmaceutics 1994; 110: 21–27
   Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacological Reviews 2001; 53: 569–596
   PubMed Web of Science ®Google Scholar
• Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 327–341
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends in Biotechnology 2000; 18: 412–420
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacological Reviews 2001; 53: 283–318
   PubMed Web of Science ®Google Scholar
• Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvascular Research 1999; 58: 312–328
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer 2004; 109: 759–767
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treatment Research 2004; 117: 249–262
   PubMedGoogle Scholar
• Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. Journal of Drug Targeting 2002; 10: 327–335
   PubMed Web of Science ®Google Scholar